跳至主要内容
临床试验/IRCT138903013862N2
IRCT138903013862N2已完成2 期

Study of efficacy and side effects of Pioglitazone in the treatment of plaque psoriasis vulgaris

Research Council of Mashhad University of Medical Sciences0 个研究点目标入组 26 人开始时间: 待定最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
26

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 80 years(—)
性别
All

入选标准

  • new cases of plaque psoriasis which don’t received systematic treatment during last 3 months and for topical treatment last month, patients complete consent form and participate to study consciously. Exclusion criteria: patients who want to leave study deliberately, sensitive to pioglitazone or the same preparations, type one diabetes mellitus, pregnant or lactating women, below 18 years old, with severe hepatic problems (hepatitis, alcoholic or non alcoholic steatohepatitis, cirrhosis), severe cardiovascular disorders (NYHA CLASS III & IV), patients prevent pregnancy only by oral contraceptives, patients that have any of these following side effects during therapy: upper respiratory tract infections and sinusitis, edema and any indicative sign of heart failure, unwanted pregnancy, weight gain, anemia, leuckopenia, hematuria, jaundice and 3 times increment of hepatic enzymes (ALT), any symptom which make patients to leave the study. Patients who used any of these drugs (Oral contraceptives, Gatifloxacin ,Insulin ,sulfunamides ,sulfunylureas, Thioridazine , Gemfibrozil).

排除标准

  • 未提供

研究者

发起方
Research Council of Mashhad University of Medical Sciences

相似试验